vs
Side-by-side financial comparison of BioLineRx Ltd. (BLRX) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $5.4M, roughly 1.2× BioLineRx Ltd.). BioLineRx Ltd. runs the higher net margin — 9.0% vs -303.5%, a 312.4% gap on every dollar of revenue.
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
BLRX vs PRLD — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4M | $6.5M |
| Net Profit | $484.0K | $-19.7M |
| Gross Margin | 83.4% | — |
| Operating Margin | -107.0% | -314.1% |
| Net Margin | 9.0% | -303.5% |
| Revenue YoY | — | 116.7% |
| Net Profit YoY | 102.6% | 38.9% |
| EPS (diluted) | $0.00 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $6.5M | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | $5.4M | — | ||
| Q2 23 | $0 | — |
| Q3 25 | — | $-19.7M | ||
| Q3 24 | — | $-32.3M | ||
| Q2 24 | $484.0K | — | ||
| Q2 23 | $-18.5M | — |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 83.4% | — | ||
| Q2 23 | — | — |
| Q3 25 | — | -314.1% | ||
| Q3 24 | — | -1145.9% | ||
| Q2 24 | -107.0% | — | ||
| Q2 23 | — | — |
| Q3 25 | — | -303.5% | ||
| Q3 24 | — | -1075.7% | ||
| Q2 24 | 9.0% | — | ||
| Q2 23 | — | — |
| Q3 25 | — | $-0.26 | ||
| Q3 24 | — | $-0.43 | ||
| Q2 24 | $0.00 | — | ||
| Q2 23 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.6M | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.9M | $58.5M |
| Total Assets | $64.6M | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $55.0M | ||
| Q3 24 | — | $153.6M | ||
| Q2 24 | $9.6M | — | ||
| Q2 23 | $10.1M | — |
| Q3 25 | — | $58.5M | ||
| Q3 24 | — | $156.4M | ||
| Q2 24 | $13.9M | — | ||
| Q2 23 | $21.1M | — |
| Q3 25 | — | $94.8M | ||
| Q3 24 | — | $197.2M | ||
| Q2 24 | $64.6M | — | ||
| Q2 23 | $58.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-19.1M |
| Free Cash FlowOCF − Capex | $-25.5M | — |
| FCF MarginFCF / Revenue | -472.8% | — |
| Capex IntensityCapex / Revenue | 1.1% | 0.0% |
| Cash ConversionOCF / Net Profit | -52.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-19.1M | ||
| Q3 24 | — | $-27.3M | ||
| Q2 24 | $-25.4M | — | ||
| Q2 23 | $-17.7M | — |
| Q3 25 | — | — | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | $-25.5M | — | ||
| Q2 23 | $-17.8M | — |
| Q3 25 | — | — | ||
| Q3 24 | — | -912.0% | ||
| Q2 24 | -472.8% | — | ||
| Q2 23 | — | — |
| Q3 25 | — | 0.0% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | 1.1% | — | ||
| Q2 23 | — | — |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -52.56× | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
